A glut of
liquid biopsy companies have emerged from universities and elsewhere in recent years to catch cancer by relying on a patient's DNA, rather than having to extract their tissue.
Not exact matches
That research will be crucial: An earlier effort by another
company, Pathway Genomics, to create a «
liquid biopsy» for cancer was greeted in September by a stern letter from the Food and Drug Administration (FDA) warning that the agency had «not found any published evidence that this test or any similar test has been clinically validated as a screening tool for early detection of cancer in high risk individuals.»
Freenome, headquartered in South San Francisco, is one of a slew of so - called
liquid biopsy (i.e., blood test)
companies to break out over the past few years.
Grail didn't invent the tests — they were first developed by researchers at Johns Hopkins and in Hong Kong, and controversial
company Pathway Genomics offers a similar
liquid biopsy.
San Diego - based DNA sequencing
company Illumina plans to build startup Grail to offer
liquid biopsy to the market.
The highlights included successful US and European ovarian cancer studies that underlined the potential of the
company's Parsortix
liquid biopsy system